Celltrion Healthcare Australia Pty Ltd

Celltrion Healthcare is committed to delivering innovative medications to promote patients’ access to advanced therapies. Our products include the world’s first antibody biosimilar, the world’s first subcutaneous formulation of infliximab, and the first high-concentration, low-volume, citrate-free, latex-free adalimumab biosimilar. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. To learn more visit: www.celltrionhealthcare.com.au

View Site Show On Map